KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Recursion Pharmaceuticals (RXRX) Other Gross PP&E Adjustments (2020 - 2025)

Recursion Pharmaceuticals' Other Gross PP&E Adjustments history spans 6 years, with the latest figure at $137.8 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 11.91% year-over-year to $137.8 million; the TTM value through Dec 2025 reached $137.8 million, up 11.91%, while the annual FY2025 figure was $137.8 million, 11.91% up from the prior year.
  • Other Gross PP&E Adjustments reached $137.8 million in Q4 2025 per RXRX's latest filing, up from -$47.8 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $137.8 million in Q4 2025 to a low of -$53.2 million in Q1 2025.
  • Average Other Gross PP&E Adjustments over 5 years is $28.6 million, with a median of -$1.7 million recorded in 2021.
  • Peak YoY movement for Other Gross PP&E Adjustments: crashed 386.52% in 2021, then soared 4881.81% in 2022.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$1.7 million in 2021, then skyrocketed by 4881.81% to $82.8 million in 2022, then grew by 11.85% to $92.6 million in 2023, then soared by 32.91% to $123.1 million in 2024, then grew by 11.91% to $137.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Other Gross PP&E Adjustments are $137.8 million (Q4 2025), -$47.8 million (Q3 2025), and -$50.3 million (Q2 2025).